Results for tag: "Hyaluronic Acid Serum"

The hyaluronic acid serum market intersects with the immune disorders drugs sector mainly through the symptomatic management of certain joint-related autoimmune conditions, like rheumatoid arthritis and osteoarthritis. Hyaluronic acid (HA), a substance naturally present in the human body, serves as a lubricant and cushioning agent in the joints and tissues. In several autoimmune disorders where joint damage is prevalent, HA serums can be introduced through injections to alleviate pain and improve joint function. Additionally, its anti-inflammatory properties have been researched in the context of immune-mediated skin conditions, leading to its topical application for skin hydration and elasticity, promoting skin health for patients with various immune disorders. Within this niche, there are a multitude of pharmaceutical and biotechnology companies that produce and supply HA serums. Some of these entities might also delve into broader therapeutic interventions for immune disorders, showcasing a diverse portfolio that extends from symptomatic management to disease-modifying treatments. Key players in this segment include Allergan, which produces HYALGAN, a treatment for knee pain in patients with osteoarthritis. Another notable company is Sanofi, offering Synvisc and Synvisc-One, both HA-based products used for joint pain relief. Genzyme (a Sanofi company) has been known for pharmaceutical developments in this area as well. Additionally, companies like Seikagaku Corporation and Zimmer Biomet also partake in the development and distribution of HA-related products, catering to a variety of medical needs encompass Show Less Read more